Terminally Ill Man Fights for Right to Medical Aid in Dying, Seeks Control Over His Final Days: 'Prefer to Die Painlessly'
Jeff McComas, who lives in Minnesota, was diagnosed with terminal intestinal cancer and wants to travel to Colorado, where medical aid in dying is legal
The 55-year-old is unable to end his life through Colorado's End-of-Life Options Act because the law requires in-state residency
McComas and two Colorado physicians are now suing Colorado, claiming the law is discriminatory and unconstitutionalA terminally ill Minnesota man is suing Colorado, claiming that the state's ban on assisting out-of-state residents with medical aid in dying is unconstitutional.
Jeff McComas, a retired engineer from Woodbury, Minnesota, was diagnosed with stage 4 intestinal cancer in January 2023. With chemotherapy, the 55-year-old was able to give himself more time. However, doctors informed him that his disease is terminal.
'The news came as a shock, and my family and I were in a state of disbelief. We have gone from shock to denial and anger, to negotiating, and finally to acceptance,' he said in a statement. 'While the side effects of cancer and its treatments can be burdensome, I fight through them, try not to complain and make the best of my time.'
'But even with my phenomenal medical team, my options in Minnesota are limited. I'll never be 'cancer free' or in remission. And at some point, the chemo will stop being effective, and either my cancer will continue spreading or the tumors will grow in size. I don't want a long, drawn-out end. I didn't pick this road, but I'm on it, and I want control in deciding when I've suffered enough.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
McComas said he wants the option of medical aid in dying (MAID). However, it's not available in his home state — a fact that he calls 'madness.' So, McComas said he wants the option to travel to Colorado, where the End-of-Life Options Act went into effect in 2016.
The law allows patients with terminal illnesses to end their lives with lethal medication — without supervision of their medical team. It's different from euthanasia because the patients themselves administer prescribed drugs to end their lives, rather than a doctor. Euthanasia is illegal in the United States.
In addition to Colorado, MAID laws have been authorized in California, Oregon, Washington, Montana, Vermont, Washington D.C., Hawaii, Maine, New Jersey and New Mexico.
However, to qualify in Colorado, individuals must be residents of the state.
'If the pain from my disease becomes unbearable, I want the option of medical aid in dying,' McComas said in a statement. 'Since I cannot die on my own terms where I live, I should have the option of traveling to Colorado to access the care there. Right now that option does not exist.'
is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more!
On May 22, nonprofit organization Compassion & Choices filed a federal lawsuit on behalf of McComas and two Colorado physicians. The complaint argues that the residency requirement of Colorado's End-of-Life Options Act violates the U.S. Constitution's Privileges and Immunities Clause which 'prohibits State officials from restricting non-resident visitors' access to medical care within its borders absent a substantial State interest and restrictions narrowly tailored to those interests.'
Additionally, the filing also claims that it violates the U.S. Constitution's Commerce Clause, which prohibits state laws that discriminate against interstate commerce by preventing providers from providing specific and appropriate medical services to otherwise qualified patients who are non-Colorado residents.
'The law is discriminatory. Appropriate health care options should not be denied to someone based on their zip code,' Jess Pezley, Compassion & Choices' senior staff attorney, said in a release. 'Firsthand experience from countless doctors and patients, and decades of data, make it clear that the residency restriction functions more as a barrier to access than as a safeguard.'
Dr. Barbara Morris and Dr. Jennifer Harbert, the physicians who brought on the lawsuit along with McComas, have both prescribed medical aid in dying medications to Colorado residents. However, they said they're often contacted by out-of-state residents seeking the same care.
'I regularly hear from people who live outside Colorado and want to come here for help with medical aid in dying,' said Morris. 'But under current law, I face the threat of criminal prosecution and civil liability if I offer non-residents the same compassionate care I provide to Colorado residents. That defies logic.'
'As the law is currently written, I cannot provide the same medical care that I deem appropriate to non-Colorado residents,' added Harbert. 'I am simply saying that all the patients I treat in Colorado should have access to the same care.'
!
The lawsuit asks the court to prohibit Colorado officials from enforcing the residency provision of the law, which limits access to medical aid in dying.
McComas explained that although he wants the option to travel to Colorado for MAID, the ultimate goal is to have the option available in Minnesota.
'I need Minnesota to pass a medical aid-in-dying bill soon,' he said. 'I won't see 2030. I want to be empowered to make my own end-of-life decisions, not having the medical community fighting to keep me alive one more painful day.
'If the end is here, I'm of the mindset that it is better a day too soon than a week too late,' McComas continued. 'I need to be allowed to pick the day and manner of my choosing, and have my wife and children at my side. I will not slowly, painfully, inexorably pass away. I will be in charge of my own passing. I'm willing to do what it takes and travel, but I'd much prefer to die painlessly in our home in Minnesota.'
Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
SUZHOU, China, June 3, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors. Title: JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trialsAbstract Number for Publication: 5557Session Type and Title: Poster Session - Gynecologic CancerSession Date and Time: 6/1/2025 9:00 AM-12:00 PM CDTPresenter: Xiaohua Wu, Fudan University Shanghai Cancer Center Methods JSKN003-101 (NCT05494918) is a Phase I study in Australia and JSKN003-102 (NCT05744427) is a Phase I/II study in China. Both trials enrolled patients with advanced solid tumors who were to receive JSKN003 monotherapy at various dose levels. Pooled results have demonstrated that JSKN003 monotherapy has promising efficacy signals in patients with PROC, and the efficacy was observed across patients with (IHC 1+/2+/3+) or without (IHC 0) HER2 expression, with or without prior bevacizumab and prior PARP inhibitor. Preliminary data from the pooled analysis of these two studies were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time. The latest findings for non-primary platinum-refractory PROC patients at a longer follow-up time were reported at this ASCO Annual Meeting. Results As of February 28, 2025, 46 PROC patients were enrolled and received JSKN003 every three weeks across five doses levels, among which 2 patients at the dose of 4.2 mg/kg, 2 patients at the dose of 5.2 mg/kg, 40 patients at the dose of 6.3 mg/kg (RP2D), 1 patient at the dose of 7.3mg/kg, and 1 patient at the dose of 8.4mg/kg. Efficacy: With a median follow-up time of 9.3 months, 46 patients were efficacy evaluable. 42 patients (91.3%) exhibited tumor shrinkage. The objective response rate (ORR) was 63.0%, the median progression-free survival (PFS) was 7.7 months, and the 9-month overall survival (OS) rate was 89.9%. Efficacy was observed across different HER2-expression subgroups. The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+). Safety: Grade 3-4 treatment-related adverse events (TRAEs) occurred in 9 patients (19.6%). Serious TRAEs were reported in 6 patients (13.0%). No TRAEs leading to death. Interstitial lung disease (ILD) was observed in 5 patients (10.9%), all were Grade 1/2. Conclusions With extended follow-up, JSKN003 demonstrated robust PFS improvement in PROC, along with early signals of OS benefit. A confirmatory trial (JSKN003-306, NCT06751485) is currently enrolling all comers regardless of HER2 expression to validate JSKN003 as a treatment option for this patient population. Title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studiesAbstract Number for Publication: 1028Session Type and Title: Poster Session - Breast Cancer - MetastaticSession Date and Time: 6/2/2025 9:00 AM-12:00 PM CDTPresenter: Yiqun Du, Fudan University Shanghai Cancer Center Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-positive (IHC 3+ or 2+/ISH+) advanced breast cancer from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, the median follow-up duration was 6.1 months. A total of 88 patients with HER2-positive breast cancer were enrolled, with the majority receiving 6.3 mg/kg or 8.4 mg/kg doses. The median age was 55 years (range: 32-79), with 77.3% ECOG PS 1. All patients had stage IV disease, with 76.1% having visceral metastases. All patients had prior anti-HER2 therapy, including 85.2% with prior ADCs or TKIs, and 55.7% having at least three prior lines treatment. Efficacy: A total of 80 T-DXd-naïve patients were enrolled, of whom 75 were evaluable for efficacy. In this population (N=75), JSKN003 demonstrated a confirmed ORR of 54.7% (95% CI: 42.7-66.2). The disease control rate (DCR) and clinical benefit rate (CBR) were 94.7% and 66.7%, respectively. Among 30 patients treated at the RP2D of 6.3 mg/kg, the confirmed ORR was 73.3%, and CBR reached 83.3%. Subgroup analyses by line of therapy showed ORRs of 66.7% in the prior first line group of 15 patients and 63.2% in the prior second line group of 19 patients, respectively. In addition, 8 patients who had previously received T-DXd were enrolled, among whom 7 had evaluable efficacy data. One patient achieved a partial response (PR), four had stable disease (SD), and tumor shrinkage was observed in four patients. These patients were analyzed separately for exploratory purposes. The median duration of response (DoR) in the overall population was 18.4 months (95% CI: 9.9-NE). Median PFS was not mature at the time of data cutoff. The 3-month and 6-month PFS rates were 88.4% (95% CI: 78.8–93.8) and 75.4% (95% CI: 62.3–84.4), respectively. Safety: 15.9% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 5.7% of patients. Dose reductions due to TRAEs occurred in 12.5% of patients, and one patient discontinued due to a TRAE. No TRAEs led to death. The most common TRAEs (≥20%) were nausea, increased alanine aminotransferase, decreased white blood cell count, vomiting, anemia, decreased appetite, thrombocytopenia, fatigue, neutropenia, and diarrhea. ILD was reported in 4 patients (4.5%), mostly Grade 1-2; one case was Grade 3. Conclusions JSKN003 demonstrated promising antitumor activity and manageable safety in heavily pretreated HER2-positive breast cancer, including patients previously treated with T-DXd. Its biparatopic HER2 antibody design may enhance target binding and contribute to the observed clinical benefit. A pivotal Phase III trial (JSKN003-301, NCT06846437) is ongoing to compare JSKN003 with T-DM1 in patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab. Title: A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumorsAbstract Number for Publication: 3022Session Type and Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor BiologySession Date and Time: 6/2/2025 1:30 PM-4:30 PM CDTPresenter: Dan Liu, Beijing Cancer Hospital Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-overexpressing (IHC 3+) metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJC) and colorectal cancer (CRC) patients from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, a total of 50 patients with HER2-overexpressing gastrointestinal tumors (27 patients in GC/GEJC and 23 patients in CRC) were enrolled and treated with JSKN003 monotherapy across 7 dose levels: 1 patient at the dose of 2.1 mg/kg, 1 patient at the dose of 4.2 mg/kg, 1 patient at the dose of 5.2 mg/kg, 43 patients at the dose of 6.3 mg/kg, 1 patient at the dose of 7.3 mg/kg, 2 patients at the dose of 8.4 mg/kg and 1 patient at the dose of 10.5 mg/kg. The median age was 60 years (range: 52-66), with 86.0% ECOG PS 1. Most patients were heavily pretreated: 38.0% had at least three lines of prior therapies, 68.0% received anti-HER2 therapy, 48.0% received Irinotecan. Efficacy: Among 48 patients who had at least one tumor assessment after baseline, JSKN003 demonstrated the ORR of 62.5% and the DCR was 93.8%. Among 27 patients with GC/GEJC, the ORR was 63.0% and DCR reached 92.6%. Among 21 patients with CRC, the ORR was 61.9% and DCR reached 95.2%. Among twenty patients with BRAF V600E-wild type, the ORR was 65.0%. Additionally, among 24 patients (4 patients in GC/GEJC and 20 patients in CRC) who were pretreated with irinotecan, the ORR achieved 58.3%. The median DoR in GC/GEJC patients was 9.6 months (95% CI: 3.0-NE), while the median DoR in CRC patients was 12.1 months (95% CI: 5.8-NE). Median PFS was 9.6 months (95%CI: 4.3, 11.6) with 70.4% PFS rate at 6 months in GC/GEJC patients. Median PFS was 13.8 months (95% CI: 6.8, NE) with 88.9% PFS rate at 6 months in CRC patients. Safety: 18.0% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 6.0% of patients. Dose reduction due to TRAEs occurred in 20.0% of patients and 16.3% at RP2D. No TEAEs led to discontinuation or death. The most common TRAEs (≥20%) were nausea, diarrhea, decreased appetite, decreased white blood cell count, anemia, fatigue, decreased neutrophil count, decreased platelet count and vomiting. ILD was reported in 3 patients (6.0%), with Grade 1 in 2 patients and Grade 2 in 1 patient. Conclusions JSKN003 demonstrated promising efficacy in heavily pretreated HER2-overexpressing (IHC3+) gastrointestinal tumors including patients previously treated with irinotecan, with a manageable and predictable safety profile. The HER2 biparatopic ADC design may contribute to the observed clinical benefit. About JSKN003 JSKN003 is a bispecific ADC developed based on KN026 using Alphamab's proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Taylor Swift Dazzles in $36K Diamond Earrings and $6K Crystal Covered Gucci Set During Outing with Selena Gomez
See all of the details from Taylor Swift's outfit from her evening out with Selena Gomez at The Monkey Bar in N.Y.C. While out to dinner on May 31, Swift wore a pair of $36,000 earrings designed by De Beers with a sparkling matching set by Gucci The special occasion came the evening after Swift announced she had acquired her mastersTaylor Swift sparkled for her girls night out with Selena Gomez! Swift, 35, and Gomez, 32, had lots to celebrate in New York City on May 31, just one day after Swift announced publicly that she had received back the rights to her music. The two friends spent the evening dining at The Monkey Bar in Midtown. Swift was spotted leaving the restaurant in a $6,000 sequin silk and wool matching set by Gucci. The neckline of the tank and the skirt's hemline included white and clear crystal sequins. The 'Cruel Summer' singer paired the black ensemble with a matching black bamboo handlebag also designed by Gucci. The bamboo bag is iconic to the brand, making its first appearance in 1947, and has since been through many eras of its own. Women of influence such as Princess Diana, Elizabeth Taylor and Grace Kelly were also fans of the bag. The cost of this all-black tote is $4,700. Related: Taylor Swift and Selena Gomez Celebrate in N.Y.C. 1 Day After Swift Gets Back Her Music Rights (Exclusive Photos) Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. As for Swift's accessories, she wore a pair of Arpeggia One Line Earring by the designer De Beers, worth $36,000. The 18k white-gold drop earrings feature 60 diamonds that weigh 4.74 carats and are hand-set by a team of the designer's craftsmen. The earrings were gifted to Swift after she wore them to the 2024 Golden Globes with her snake-green Gucci gown. Swift wore a custom TNT diamond tennis bracelet designed by Wove Made and Michelle Wie West with a starting value of $5,680. Swift had also been photographed wearing the same bracelet the evening before she announced she had acquired her masters on May 29. On her finger, she wore a Cloud Offset Pear Ring designed by Shahla Karimi Jewelry in SoHo N.Y.C. Hailey Bieber has also been spotted wearing the designer's rings. Swift completed her evening outfit with a pair of Gucci silver platform sandals. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The evening out in Manhattan, came just after Swift announced that she regained ownership of her masters — which allows her to once again be in control of her music catalog following a public ownership feud involving record executive Scooter Braun. 'You belong with me. 💚💛💜❤️🩵🖤,' Swift wrote on her Instagram carousel, on May 30, including a nod to her 2008 hit of the same name from her album Fearless. Gomez celebrated her BFF after she made the news public, writing in an Instagram Stories post, 'Yes you did that Tay. So proud!' Read the original article on People
Yahoo
2 hours ago
- Yahoo
Christina Haack Says Ex Josh Hall Claims His Mom Was Accosted by Stranger in Yoga Class Who Called Him ‘a Thief'
Christina Haack is opening up about her divorce settlement from Josh Hall Hall filed for divorce on July 15, 2024 Haack claimed in a new podcast interview that Hall said during his mediation that his mother was accosted during a yoga class due to the public nature of the divorceChristina Haack is sharing new insight into her divorce proceedings. Haack, 41, finalized her divorce from ex-husband Josh Hall in May. In a recent interview on Sirius XM's Radio Andy, Haack shared details about Hall's claims from the divorce mediation. Hall, 43, filed for divorce from Haack on July 15, 2024, citing irreconcilable differences, per documents obtained by PEOPLE at the time. "I will say something that I thought was a little bit funny at mediation," Hacck began in the episode, released on Monday, June 2. "So, at one point, this thing came up where his reputation got hurt or whatever 'cause you know, he was a reality TV star before me, and now he can't be a reality TV star anymore because nobody likes him." "His mom was at yoga and while she was doing her yoga poses, a fellow yogian said, 'Your son is a thief,' during yoga class," Haack continued. The Christina on the Coast star then said that the divorce settlement "was resolved in mediation after I think 12 hours." PEOPLE reached out to a representative for Hall, but did not immediately hear back. Haack went on to credit her attorney for assisting her in the settlement. "My attorney, she's magic," she said. When asked if she needed to pay alimony to Hall, Haack remained tight-lipped, saying, "I don't know if I'm allowed to talk about it. It'll be in the doc soon. It'll be public knowledge in a few." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories. Haack and Hall were married in an Oct. 6, 2021, ceremony in Hawaii. The divorce documents obtained by PEOPLE list July 8, 2024, as the couple's official date of separation. Hall was Haack's third husband. She was previously married to Flip or Flop costar Tarek El-Moussa, with whom she shares two children: Taylor, 13, and son Brayden, 8. The couple divorced in 2018, and Haack married Ant Antstead later that same year. She and Anstead, who divorced in 2020, are parents to son Hudson, 4. Read the original article on People